LoginSignup
BIO

BioNTech

Stock
Stock
ISIN: DE000A0V9BC4
DE000A0V9BC4

Price

Price

Frequently asked questions

What is BioNTech's market capitalization?

The market capitalization of BioNTech is $26.51B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for BioNTech?

BioNTech's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -2.269. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for BioNTech's stock?

Currently, 19 analysts cover BioNTech's stock, with a consensus target price of $114.43. Analyst ratings provide insights into the stock's expected performance.

What is BioNTech's revenue over the trailing twelve months?

Over the trailing twelve months, BioNTech reported a revenue of $2.91B.

What is the EBITDA for BioNTech?

BioNTech's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$568.79M. EBITDA measures the company's overall financial performance.

What is the free cash flow of BioNTech?

BioNTech has a free cash flow of $2.55B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of BioNTech's stock?

The 5-year beta for BioNTech is 0.22. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does BioNTech have, and what sector and industry does it belong to?

BioNTech employs approximately 6,133 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of BioNTech's shares?

The free float of BioNTech is 214.95M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $26.51B

5Y beta

 0.22

EPS (TTM)

 -2.269

Free Float

 214.95M

Revenue (TTM)

 $2.91B

EBITDA (TTM)

 -$568.79M

Free Cashflow (TTM)

 $2.55B

Analyst Ratings

The price target is $114.43 and the stock is covered by 19 analysts.

Buy

8

Hold

9

Sell

2

Information

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

6,133

Biotechnology & Drugs

Health Care

Identifier

ISIN

DE000A0V9BC4

Knockouts

Join the conversation
Sign upLogin